---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211080"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-08-30T23:59:59+00:00"
generated_at: "2026-05-31T06:51:41.874301+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Phase 3 trial IDMC recommends continuation; PFS endpoint expected H1 2025

## Summary
- IDMC recommends Phase 3 trial of IO102-IO103 + pembrolizumab continue without modifications after interim analysis.
- Interim ORR analysis did not meet pre-specified high statistical bar (p≤0.005); most alpha preserved for PFS.
- Primary endpoint PFS event-driven at 226 events; trial 89% powered to detect 35% risk reduction; projected H1 2025.
- No new safety signals observed; 407 patients enrolled across 100+ centers in US, EU, Australia, and elsewhere.
- Phase 2 basket trial data for NSCLC and SCCHN accepted for presentations at ESMO and other fall meetings.

## SEC filing metadata
- accession: 0001193125-24-211080
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-08-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524211080/0001193125-24-211080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524211080/d889003d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211080
- JSON: https://secwatch.observer/filing/0001193125-24-211080.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.